Skip to content
Biotechnology

FY25 Half Year Results – Shareholder Update

BTC Health Limited (ASX:BTC) 2 mins read

Highlights:

• BTC statutory profit after tax of $4.9m (1H FY24: $1.7m)
• BTC and investee companies consolidated 1H FY25 performance:

• revenue up 9% to $5.3m (1H FY24: $4.9m) 
• gross profit up 6% to $2.3m (1H FY24: $2.2m)
• operating expenses remain well controlled at $2.1m (1H FY24: $2.1m)
• EBITDA of $0.2m (1H FY24: $0.1m)
• net cash reserves of $2.7m (1H FY24: $2.4m)

• Investee businesses greatly diversified and strengthened with:

• acquisition of the Corcym heart valve business – adding $3.6m revenue per annum
• award of a $5m 5-year ECMO contract with Royal Childrens’ Hospital - Melbourne
• Rhythmic and Elasto-Q infusion pumps approved for private health reimbursement
• Bronchitol and Aridol license for Aus/NZ extended indefinitely

Executive Chairman and Managing Director Dr Richard Treagus commented, "We have significantly strengthened and diversified the business over the last 6 months, and with a solid foundation established, we are well positioned to continue the positive momentum throughout 2025.”

READ THE FULL ANNOUNCEMENT HERE

READ THE INVESTOR PRESENTATION HERE


About us:

About BTC Health
BTC Health is a registered Pooled Development Fund and has investments in three core medical companies:

- BTC Speciality Health, which is responsible for the commercialisation and distribution of medical devices and medical consumables in the therapeutic categories of acute pain management and neurospinal surgery.
- BTC Pharma, which undertakes the registration, development, sales and marketing of specialised pharmaceutical medicines, that serve niche markets and rare diseases.
- BTC Cardio, which is dedicated to the marketing and distribution of highly specialised cardiovascular medical equipment and single-use consumable products used by cardiac surgeons and critical care experts.


Contact details:

For more information, please contact:

BTC Health Limited (ASX:BTC)
Dr Richard Treagus 
Executive Director
T:  +61 417 520 509 
E: [email protected]

Tracy Weimar
Company Secretary
T: +61 3 9692 7222
E: t[email protected]

Investor Relations
The Capital Network 
Julia Maguire
T: +61 2 7257 7338
E: [email protected]

More from this category

  • Biotechnology
  • 12/12/2025
  • 11:40
4DMedical Limited (ASX:4DX)

4DMedical secures $30.2 million with options underwrite

Highlights• $30.2 million in funding secured by entering into an underwriting agreement that ensures the exercise of all the 4DXO listed options• Additional funding results in a proforma cash balance as at 30 September 2025 of $63.7 million • 4DMedical is experiencing unprecedented interest in CT:VQ™, with multiple contract discussions underway, positioning CY26 as a transformational year Melbourne, Australia, 12 December 2025: 4DMedical Limited (ASX: 4DX, “4DMedical” or the “Company”) today announces it has entered into an option underwriting agreement (Underwriting Agreement) with Bell Potter Securities Limited (Underwriter) to fully underwrite the exercise of the 4DXO listed options on issue,…

  • Biotechnology
  • 12/12/2025
  • 10:58
EBR Systems, Inc. (ASX:EBR)

First implant in the Totally Leadless CRT (TLC-AU) Study

Key Highlights • First patient enrolment and implant in the Totally Leadless CRT (TLC-AU) study by Dr Paul Gould from the Princess Alexandra Hospital, Brisbane • TLC-AU is a feasibility study into using the WiSE® System alongside a leadless pacemaker to achieve totally leadless CRT • The study represents a significant strategic milestone as EBR evaluates WiSE as a potential first-line therapy for treating newly diagnosed heart failure patients • TLC-AU could meaningfully expand EBR’s addressable market Sunnyvale, California; 12 December 2025: EBR Systems, Inc., developer of the world’s only wireless cardiac pacing device for heart failure, announces the first…

  • Biotechnology
  • 10/12/2025
  • 10:19
OncoSil Medical Limited (ASX:OSL)

First OncoSil treatment in United Kingdom

Sydney, Australia – 10 December 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the first commercial patient treatment in the UK using the OncoSil™ device. The successful treatment was performed on 9 December 2025 at Southampton General Hospital (University Hospital SouthamptonNHS Foundation Trust), a recognised centre of excellence in oncology. Following the hospital’s participation in the TRIPP-FFX clinical study, this significant milestone marks the transition from clinical trial involvement to the commencement of OncoSil’s commercial operations…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.